Small cap social media gaming stockZynga Inc (NASDAQ: ZNGA) reportedQ2 2017 earnings after the Wednesday market close. Revenue was above guidance by $9.2 million and up 15% year-over-year to $209.2 million whilenet income was $5.1 million, better than guidance by $11.1 million and an improvement of $9.5 million year-over-year.
The earnings release noted:
In terms of our bookings performance, our teams delivered $209.2 million, beating our guidance by $4.2 million and up 20% year-over-year. This quarter represented our strongest revenue and bookings performance in four years and our best year-over-year performance since Q2 2015. The over delivery in the quarter was driven by better than expected results from our portfolio of live services
Top Small Cap Stocks To Own For 2019: Array BioPharma Inc.(ARRY)
- [By Lisa Levin] Gainers
Loxo Oncology Inc (NASDAQ: LOXO) rose 32.7 percent to $65.00 in pre-market trading after the company reported that larotrectinib trial demonstrated 76 percent confirmed objective response rate.
Dynavax Technologies Corporation (NASDAQ: DVAX) shares rose 22 percent to $7.20 in the pre-market trading session after the company on Friday presented updated data for SD-101 in combination with KEYTRUDA.
Puma Biotechnology Inc (NASDAQ: PBYI) rose 21.7 percent to $99.75 in pre-market trading as the company disclosed positive PB272 Phase 2 data from TBCRC 022 trial at ASCO17.
Helios and Matheson Analytics Inc (NASDAQ: HMNY) shares rose 20.7 percent to $3.21 in pre-market trading after the company reported that RedZone has acquired all the assets of Trendit including three technology patents.
Forestar Group Inc. (NYSE: FOR) rose 13.1 percent to $16.05 in pre-market trading after D.R. Horton, Inc. (NYSE: DHI) proposed to buy 75 percent of Forestar Group for $16.25 per share in cash.
TG Therapeutics Inc (NASDAQ: TGTX) shares rose 12 percent to $15.50 in pre-market trading after the company said Phase 3 GENUINE trial met primary endpoint with TG-1101 + ibrutinib increasing overall response rate by >70 percent versuss ibrutinib alone.
Gigamon Inc (NYSE: GIMO) gained 10.8 percent to $43.55. Reuters reported that Gigamon is exploring a potential sale.
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) rose 8.7 percent to $6.00 in pre-market trading after the company announced Rapivab pediatric sNDA acceptance by the FDA.
Array Biopharma Inc (NASDAQ: ARRY) rose 7.2 percent to $8.77 in pre-market trading after gaining 5.68 percent on Friday.
Ehi Car Services Ltd (ADR) (NYSE: EHIC) shares rose 6.4 percent to $10.76 in pre-market trading. eHi Car Services posted Q1 earnings of $0.06 on sales of $89.43 million.
Skyworks Solutions Inc (NASDAQ: SWKS) rose 5.9 percent to $114.79 in pre-market trading after gaining 0.69 percent on Friday.
- [By ]
Some of our newest plays are getting plenty of attention thanks to the biotech buying spree. Array Biopharma (NASDAQ:ARRY) is an instant winner for you thanks to yesterdays 18% pop. And your core holding XBI continues to rake in the gains.
- [By Lisa Levin]
Healthcare shares gained around 0.43 percent in trading on Friday. Meanwhile, top gainers in the sector included DexCom, Inc. (NASDAQ: DXCM), and Array Biopharma Inc (NASDAQ: ARRY).
Top Small Cap Stocks To Own For 2019: Trevena, Inc.(TRVN)
- [By Maxx Chatsko]
Shares of clinical-stage biopharma Trevena (NASDAQ:TRVN) fell nearly 12% today after it reported full-year 2016 earnings. The pre-revenue company didn’t announce any surprises one way or the other. However, investors appear to be considering the near-term consequences of swelling expenses that won’t be offset by product sales anytime soon.
- [By Chris Lange]
Trevena Inc. (NASDAQ: TRVN) reported positive results from two late-stage clinical trials that work to treat post-surgical pain. The company intends to submit these results to the FDA for a marketing approval agreement in the fourth quarter. Previously, oliceridine was approved for a breakthrough designation by the agency.
- [By Lisa Levin] Gainers
Trevena Inc (NASDAQ: TRVN) rose 10.8 percent to $3.60 in pre-market trading after dropping 4.97 percent on Wednesday.
Yum China Holdings Inc (NYSE: YUMC) rose 10.2 percent to $31.05 in pre-market trading after the company reported upbeat earnings for its first quarter.
Seres Therapeutics Inc (NASDAQ: MCRB) rose 9.1 percent to $11.39 in pre-market trading after dropping 5.26 percent on Wednesday.
Plug Power Inc (NASDAQ: PLUG) rose 8.9 percent to $2.45 in pre-market trading after surging 73.08 percent on Wednesday.
Coach Inc (NYSE: COH) rose 6.7 percent to $41.98 in pre-market trading. Coach named Ian Bickley as President, Global Business Development and Strategic Alliances.
Sapiens International Corporation N.V. (NASDAQ: SPNS) shares rose 6.1 percent to $13.91 in pre-market trading after gaining 0.54 percent on Wednesday.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) rose 6.1 percent to $149.15 in pre-market trading. Jazz Pharma reached a settlement with Hikma Pharma related to Xyrem patent case. Mizuho downgraded Jazz from Buy to Neutral.
Interactive Brokers Group, Inc. (NASDAQ: IBKR) shares rose 6 percent to $36.72 in pre-market trading after declining 0.03 percent on Wednesday.
Rewalk Robotics Ltd (NASDAQ: RWLK) rose 5.3 percent to $2.00 in pre-market trading after the company disclosed that the U.S. Department of Veterans Affairs purchased 28 added Exoskeleton Systems.
Merrimack Pharmaceuticals Inc (NASDAQ: MACK) rose 5.1 percent to $3.29 in pre-market trading. Merrimack declared a $1.06 special dividend.
BioTime, Inc. (NYSE: BTX) shares rose 4.8 percent to $3.50 in pre-market trading. BioTime, reported the formation of new subsidiary AgeX Therapeutics, Inc.
Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) shares rose 4.8 percent to $12.26 in pre-market trading after gaining 0.69 percent on Wednesday.
Bed Bath & Beyond Inc. (NASDAQ: BBBY) rose 3.6 percent to $39.15 in pre-market trading after the company posted better-than
- [By Lisa Levin]
Trevena Inc (NASDAQ: TRVN) shares dropped 36 percent to $4.55 despite a positive development in Phase 3 trials. Trevena announced positive top-line results from ongoing Phase 3 trials called "APOLLO-1" and "APOLLO-2." The studies evaluated the safety of Trevena's oliceridine therapy in patients for 48 hours following bunionectomy and 24 hours following abdominoplasty.
- [By Paul Ausick]
Trevena Inc. (NASDAQ: TRVN) dropped about 6.3% Thursday, to post a new 52-week low of $3.70 after closing at $3.95 on Wednesday. The stock’s 52-week high is $9.73. Volume was nearly 5 times the daily average of around 700,000 shares. The company’s pain-killing drug got mixed results in a trial result reported Tuesday.
Top Small Cap Stocks To Own For 2019: Baytex Energy Corp(BTE)
- [By Logan Wallace]
Baytex Energy (TSE:BTE) (NYSE:BTE) had its price target raised by equities researchers at TD Securities from C$4.50 to C$5.50 in a report issued on Friday. The brokerage currently has a “hold” rating on the stock. TD Securities’ price target points to a potential downside of 0.90% from the company’s current price.